Intra Vitreal Injections or Implants - FOI Response Register

How many of the following Intra-Vitreal injections/implants has your Board administered in the four-month period from January to April 2025:

• Aflibercept

162

• Bevacizumab

Nil

• Brolucizumab

Nil

• Dexamethasone

Nil

• Faricimab

15

• Fluocinolone acetonide

Nil

• Ranibizumab – Lucentis

<10

• Ranibizumab – Biosimilar (Ongavia, Ximluci, Byooviz, Rimmyrah)

<10

Where we have given <10 answers, given the small numbers of patients involved; the specific nature of the health conditions referred to; the size of Shetland’s population; the specific treatments; and the short timeframe, NHS Shetland considers that providing any more specific information carries a high risk of identifying individuals. As such and in accordance with FOISA s 16(1), NHS Shetland confirms that it holds the information requested but that it is exempt from disclosure under FOISA s 38(1)(b) as read with s 38 (2A) as the information constitutes personal data and disclosure would breach the confidentiality of the data subjects.